CLYM
Climb Bio, Inc. · Healthcare · Market cap $620.3M
Insiders sold $1.4M net in the last 90 days ·1 seller, 0 buyers· 1 of 1 sale under Rule 10b5-1 plans· latest Form 4 filed Sep 17, 2026
Insider Buying
$780K
reported purchases (SEC code P)
Insider Selling
$2.7M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Sep 30, 2026
Thomas Stephen Basil
Climb Bio, Inc. (CLYM) has 7 SEC Form 4 filings (15 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Sep 30, 2026.
Inside the rolling window, 3 insiders at Climb Bio, Inc. reported 3 open-market purchases totaling $780K and 6 open-market sales totaling $2.7M. The most active filer is Director Thomas Stephen Basil with 5 filings. Insiders have net sold $1.8M over the trailing 6 months. The most recent open-market filing is a sale of 100,000 shares by Director Thomas Stephen Basil, dated Sep 15, 2026, worth $1.4M.
- Industry:Biotechnology
- CEO:Aoife Brennan BCh MMSc
- Employees:28
- HQ:Wellesley Hills, MA, US
- IPO:2021-08-10
| Source | |||||||
|---|---|---|---|---|---|---|---|
Thomas Stephen BasilFirst in 7 months | Director | Sale | 100,000 | $1.4M | Sep 17 | -23.2% | SEC ↗ |
Brennan AoifeFirst filing | President and CEO | Sale | 30,902 | $407K | Jun 30 | -17.2% | SEC ↗ |
| Director | Sale | 33,687 | $236K | Feb 27 | +51.0% | SEC ↗ | |
| Director | Sale | 16,313 | $114K | Feb 27 | +51.0% | SEC ↗ | |
Thomas Stephen BasilFirst filing | Director | Sale | 90,000 | $471K | Feb 17 | +92.5% | SEC ↗ |
Thomas Stephen BasilFirst filing | Director | Sale | 10,000 | $58K | Feb 17 | +92.5% | SEC ↗ |
| Director, 10% Owner | Purchase | 7,111 | $25K | Jan 7 | +157.1% | SEC ↗ | |
| Director, 10% Owner | Purchase | 213,099 | $465K | Dec 15 | +183.5% | SEC ↗ | |
| Director, 10% Owner | Purchase | 101,462 | $290K | Dec 15 | +183.5% | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does CLYM have?
Climb Bio, Inc. (CLYM) has 7 SEC Form 4 filings (15 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Sep 30, 2026.
When was the most recent SEC Form 4 filing for CLYM?
The most recent Form 4 filing for CLYM on Tracefour is dated Sep 30, 2026.
Who is the most active insider at CLYM?
The most active SEC Form 4 filer at CLYM in the rolling window is Director Thomas Stephen Basil, with 5 filings.
What is the net insider flow at CLYM over the last 6 months?
Over the trailing 180 days, insiders at CLYM have net sold $1.8M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at CLYM in the current window?
Inside the rolling window, insiders at CLYM bought $780K and sold $2.7M based on SEC Form 4 filings.
Can I get alerts for CLYM insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Climb Bio, Inc. (CLYM). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Climb Bio, Inc. is in the Healthcare sector.